The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society. More

Press Releases

Human Immunodeficiency Virus

Recent Publications

Reversion and T Cell Escape Mutations Compensate the Fitness Loss of a CD8+ T Cell Escape Mutant in Their Cognate Transmitted/Founder Virus.
Song H, Hora B, Bhattacharya T, Goonetilleke N, Liu MK, Wiehe K, Li H, Iyer SS, McMichael AJ, Perelson AS, Gao F. PLoS One. 2014 Jul 16;9(7):e102734. doi: 10.1371/journal.pone.0102734. eCollection 2014.

HIV-1 Antibodies and Vaccine Antigen Selectively Interact with Lipid Domains.
Hardy GJ, Wong GC, Nayak R, Anasti K, Hirtz M, Shapter JG, Alam SM, Zauscher S. Biochim Biophys Acta. 2014 Jul 11. pii: S0005-2736(14)00251-X. doi: 10.1016/j.bbamem.2014.07.007. [Epub ahead of print]

Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?
Bonsignori M. Expert Rev Vaccines. 2014 Jul 12:1-4. [Epub ahead of print]

Video Presentations

Broadly neutralizing HIV-1 antibody identified in a lupus patient
March 11, 2014
Dr. Barton Haynes, DHVI and Duke CHAVI-ID Director, discusses recent findings from a study led by DHVI investigators in which a broadly neutralizing antibody was identified in a lupus patient who was chronically infected with HIV.